Every 8-K that Ernexa Therapeutics Inc. (ERNA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ERNA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ERNA filings page.
Ernexa Therapeutics Inc. (ERNA) reported that on September 16, 2026 it made a corporate fact sheet and an investor presentation available to investors, furnished as Exhibits 99.1 and 99.2 to this report under a Regulation FD disclosure.
The company states that these materials, including their “Forward-Looking Statements” disclosure, are incorporated by reference into this Item 7.01 and will also be accessible on its investor relations website starting September 17, 2026. Ernexa explains that it uses its website as a regular channel to distribute important and time‑critical company information, while clarifying that the furnished materials are not deemed filed for purposes of Section 18 of the Exchange Act.
Ernexa Therapeutics Inc. (ERNA) reports that its board of directors has appointed Robert J. Spiegel, M.D. as a director, effective September 14, 2026. He will serve until a successor is duly elected and qualified or until earlier death, resignation, or removal.
Dr. Spiegel will be compensated under Ernexa’s Board of Directors Compensation Plan that became effective August 15, 2026 and is described in the company’s Form 10-Q for the quarter ended June 30, 2026. The company states there are no appointment-related arrangements, no family relationships with current leadership, and no related-party transactions with Dr. Spiegel that are reportable under Item 404(a) of Regulation S-K.
Ernexa Therapeutics Inc. furnished an updated investor presentation as part of a current report on Form 8-K. The July 2026 presentation, attached as Exhibit 99.1, updates materials first posted in February 2026 and will also be available on the company’s investor relations website.
The company states that it routinely uses its website to distribute important information, including press releases, investor presentations and financial data, and offers email alerts when new materials are posted. The information in this item and Exhibit 99.1 is being provided as “furnished,” not “filed,” under the Exchange Act.
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the May 6, 2026 record date, there were 1,166,333 common shares outstanding, and 619,741 shares, or about 53.13%, were represented, establishing a quorum.
Stockholders elected five directors to serve until the 2027 annual meeting, ratified Haskell & White LLP as independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. No other matters were brought to a vote.
Ernexa Therapeutics Inc. announced that Senior Vice President of Finance Sandra Gurrola has submitted her resignation, effective July 3, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.
After her resignation becomes effective, Ms. Gurrola has agreed to provide transition assistance on a part-time basis for up to 10 hours per week through the filing of Ernexa’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa has begun a search for her successor and plans to use additional outside support to help with finance, accounting, and reporting until a replacement is appointed.
Ernexa Therapeutics Inc. approved a structural change to its capital by filing a Certificate of Amendment in Delaware to implement a 1-for-25 reverse stock split of its common stock. This consolidates every 25 existing shares into 1 share.
The reverse split became effective for trading on Nasdaq at market open on May 4, 2026, when the common stock began trading on a split-adjusted basis under the existing ERNA symbol. The company’s common stock now carries a new CUSIP number, 114082407, following the reverse stock split.
Ernexa Therapeutics Inc. disclosed that Nasdaq has notified the company its common stock no longer meets the minimum bid price requirement of $1.00 per share for 30 consecutive business days under Nasdaq Listing Rule 5550(a)(2). Because Ernexa completed a reverse stock split within the past year, it is not eligible for the standard 180‑day automatic grace period and instead plans to request a hearing before a Nasdaq Hearing Panel. The hearing request will stay any suspension or delisting action while the Panel reviews the case and may grant an extension of up to 180 days from the notice date, but there is no assurance the company will regain compliance or maintain its Nasdaq Capital Market listing.
Ernexa Therapeutics Inc. furnished an updated investor presentation on February 26, 2026, as Exhibit 99.1 to a Form 8-K. The deck refreshes a prior presentation from December 11, 2025 and is also available through the Investor Relations section of the company’s website.
The company explains that it routinely uses its website to share press releases, investor presentations and financial information, and encourages investors to monitor the News and Investor Relations pages. The material in Item 7.01 and Exhibit 99.1 is furnished, not filed, and is not subject to Exchange Act Section 18 liabilities or automatically incorporated into other SEC filings.
Ernexa Therapeutics Inc. entered into agreements for a best-efforts public offering of common stock and warrants, raising approximately $10.5 million in gross proceeds. The deal covers 21,000,000 shares of common stock (or equivalents) and warrants to purchase up to 21,000,000 shares, at a combined price of $0.50 per share (or equivalent) and warrant.
The warrants are immediately exercisable at $0.68 per share and will expire on the earlier of five years from issuance or 180 days after the first-cohort Phase 1 ERNA-101 data release. Pre-funded warrants for 2,000,000 shares carry a $0.01 exercise price. The Nasdaq-listed warrants trade under the symbol ERNAW.
Brookline Capital Markets, a division of Arcadia Securities, acted as placement agent, earning cash fees and 231,576 shares as compensation. Ernexa plans to use net proceeds to advance its cell therapy programs, working capital, and general corporate purposes, and has agreed to 90-day issuance restrictions and officer/director lock-ups.